Matthias A Karajannis1, Rosalie E Ferner. 1. aDepartments of Pediatrics and Otolaryngology, Division of Pediatric Hematology/Oncology, NYU Langone Medical Center, New York, USA bDepartment of Neurology, Guy's and St Thomas' NHS Foundation Trust, and Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.
Abstract
PURPOSE OF REVIEW: Over the past decade, substantial insight into the biological function of the tumor suppressors neurofibromin (NF1) and Merlin (NF2) has been gained. The purpose of this review is to highlight some of the major advances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the development of novel therapies for these disorders. RECENT FINDINGS: The development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium. SUMMARY: Clinical trials with molecular-targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise for improving the morbidity and mortality of individuals affected with these disorders.
PURPOSE OF REVIEW: Over the past decade, substantial insight into the biological function of the tumor suppressors neurofibromin (NF1) and Merlin (NF2) has been gained. The purpose of this review is to highlight some of the major advances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the development of novel therapies for these disorders. RECENT FINDINGS: The development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium. SUMMARY: Clinical trials with molecular-targeted therapies have become a reality for neurofibromatosispatients, and hold substantial promise for improving the morbidity and mortality of individuals affected with these disorders.
Authors: Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander A Vinks; Alan Cantor; Bruce Korf; John Perentesis; David H Gutmann; Elizabeth Schorry; Roger Packer; Michael J Fisher Journal: Pediatr Blood Cancer Date: 2014-06 Impact factor: 3.167
Authors: Scott R Plotkin; Vanessa L Merker; Chris Halpin; Dominique Jennings; Michael J McKenna; Gordon J Harris; Fred G Barker Journal: Otol Neurotol Date: 2012-08 Impact factor: 2.311
Authors: Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis Journal: Neuro Oncol Date: 2014-02-04 Impact factor: 12.300
Authors: Scott R Plotkin; Vanessa L Merker; Alona Muzikansky; Fred G Barker; William Slattery Journal: Otol Neurotol Date: 2014-01 Impact factor: 2.311
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Filippo G Giancotti; Alexander Filatov; Anna Derman; Tsivia Hochman; Judith D Goldberg; Emilio Vega; Jeffrey H Wisoff; John G Golfinos; Amanda Merkelson; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: Doreen Pachow; Nadine Andrae; Nadine Kliese; Frank Angenstein; Oliver Stork; Annette Wilisch-Neumann; Elmar Kirches; Christian Mawrin Journal: Clin Cancer Res Date: 2013-02-13 Impact factor: 12.531
Authors: A S Yamashita; G S Baia; J S Y Ho; E Velarde; J Wong; G L Gallia; A J Belzberg; E T Kimura; G J Riggins Journal: J Neurooncol Date: 2014-03-26 Impact factor: 4.130
Authors: Eva Dombi; Simone L Ardern-Holmes; Dusica Babovic-Vuksanovic; Fred G Barker; Steve Connor; D Gareth Evans; Michael J Fisher; Stephane Goutagny; Gordon J Harris; Diego Jaramillo; Matthias A Karajannis; Bruce R Korf; Victor Mautner; Scott R Plotkin; Tina Y Poussaint; Kent Robertson; Chie-Schin Shih; Brigitte C Widemann Journal: Neurology Date: 2013-11-19 Impact factor: 9.910
Authors: Anne M Comi; Mustafa Sahin; Adrienne Hammill; Emma H Kaplan; Csaba Juhász; Paula North; Karen L Ball; Alex V Levin; Bernard Cohen; Jill Morris; Warren Lo; E Steve Roach Journal: Pediatr Neurol Date: 2016-03-16 Impact factor: 3.372
Authors: George S Stoyanov; Deyan Dzhenkov; Peter Ghenev; Bogomil Iliev; Yavor Enchev; Anton B Tonchev Journal: Med Oncol Date: 2018-01-31 Impact factor: 3.064
Authors: Matthias A Karajannis; Audrey Mauguen; Ekrem Maloku; Qingwen Xu; Erin M Dunbar; Scott R Plotkin; Anna Yaffee; Shiyang Wang; J Thomas Roland; Chandranath Sen; Dimitris G Placantonakis; John G Golfinos; Jeffrey C Allen; Nicholas A Vitanza; Luis A Chiriboga; Robert J Schneider; Jingjing Deng; Thomas A Neubert; Judith D Goldberg; David Zagzag; Filippo G Giancotti; Jaishri O Blakeley Journal: Mol Cancer Ther Date: 2021-06-17 Impact factor: 6.261